New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...

Related Keywords

United Kingdom ,Oslo ,Norway ,Norwegian ,Oddbjorn Straume ,Prnewswire Bergenbio ,Jan Lilleby ,Cristina Oliva ,Martin Olin ,Oslo Stock Exchange ,European Society Of Clinical Oncologists ,Haukeland University Hospital In Bergen ,Non Small Cell Lung Cancer ,European Society ,Clinical Oncologists ,Annual Meeting ,Assistant Professor ,Clinical Science ,Haukeland University Hospital ,Investigator Led Study ,Chief Medical Officer ,Media Relations ,Norwegian Securities Trading ,Bergenbio Asa ,